Anti-angiogenic activity of ShengMaBieJia decoction in vitro and in acute myeloid leukaemia tumour-bearing mouse models

Abstract

Context: ShengMaBieJia decoction (SMBJD) is used to treat solid and hematological tumours; however, its anti-angiogenesis activity remains unclear.Objective: This study verified the anti-angiogenic effects of SMBJD in vitro and in tumour-bearing acute myeloid leukaemia (AML) mouse models. Materials and methods: In vivo, the chicken chorioallantoic membrane (CAM) and BALB/c null mouse xenograft models were treated with SMBJD (0, 2, 4, and 8 mg/mL) for 48 h and for 2 weeks, respectively. Anti-angiogenic activity was assessed according to microvessel density (MVD) and immunohistochemistry (IHC) targeting CD31 and VEGFR2. In vitro, proliferation viability, migratory activity and tube formation were measured. Western blots and polymerase chain reaction (PCR) assays were used to examine the levels of PI3K, Akt, and VEGF. Results: HPLC analyses revealed the active constituents of SMBJD such as liquiritin, cimifugin, ferulic, isoferulic, and glycyrrhizic acids. In vitro, SMBJD treatment decreased cellular migration, chemotaxis, and tube formation at non-cytotoxic concentrations (2, 4, and 8 mg/mL) in a time-and dose-dependent manner. The dosage of less than IC 20 is considered safe. In vivo, CAM models exhibited a decrease in MVD, and the tissues of xenografted mice possessed reduced CD31 and VEGFR2 expression. Conditioned media (CM) from AML cells (HL60 and NB4 cells) treated with non-cytotoxic doses of SMBJD inhibited chemotactic migration and tube formation in vitro. Both CM (HL60) and CM (NB4) exhibited downregulated expression of PI3K, Akt, and VEGF. Discussion and conclusions: SMBJD inhibited angiogenesis in AML through the PI3K/AKT pathway, which might be combined with targeted therapy to provide more effective treatment.

Suchilactone inhibits the growth of acute myeloid leukaemia by inactivating SHP2

“… 2020 ) and that the ShengMaBieJia decoction (SMBJD) inhibits the angiogenesis in AML by acting on the PI3K/AKT pathway (Wang et al. 2020 ). Here, we reported that suchilactone, an active component from Monsonia angustifolia , could effectively inhibit the proliferation of the human AML cell line SHI-1 and promote apoptosis to alleviate the progression of AML in SCID mice.…”

Traditional uses, phytochemistry, pharmacology, quality control and clinical studies of Cimicifugae Rhizoma: a comprehensive review

“…Different doses (0, 2, 4, 8 mg/mL) of Shengma Biejia Decoction (SMBJT) were applied to the chicken chorioallantoic membrane and tumor-bearing acute myeloid leukemia mouse models, respectively. SMBJT reduced microvessel density (MVD), immunohistochemical targeting CD31 and vascular endothelial growth factor receptor 2 expression to repress PI3K/Akt pathway targeted anti-angiogenesis [ 107 ].…”

Shengma Biejia Decoction Inhibits Cell Growth in Multiple Myeloma by Inducing Autophagy-Mediated Apoptosis Through the ERK/mTOR Pathway

“…Subsequently, a series of basic studies confirmed that SMBJD could inhibit the proliferation of human acute myeloid leukemia HL-60 cells and induce apoptosis by regulating the MAPK signaling pathway. Moreover, non-cytotoxic concentrations (2, 4, and 8 mg/ml) of SMBJD could decrease cellular migration, chemotaxis, and tube formation of human umbilical vein endothelial cells in a time and dose-dependent manner ( Wang et al, 2020 ). In addition, SMBJD has been used as an adjuvant treatment for MM, with remarkable clinical effects.…”